Therapeutic Innovations, Diminishing Returns, and Control Rate Preservation
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
Many aspects of therapeutics development, not least the exorbitant costs, incentivize risk-averse approaches modeled on previously successful therapies that, coupled with sophisticated strategies for “market differentiation”, might offer the best return on investment for industry, and sometimes also lead to meaningful improvements in public health. Even for these narrowly pragmatic aims, such strategies may have a natural life cycle. The Government Accountability Office on New Drug Development recently summarized empirical evidence for a rising failure rate in phase III clinical testing of new agents15. While other factors surely play a role, declining control rates may be an essential emblem of a broader process of maturation. Assuming theoretical limits on optimal human health and lifespan, the Malthusian relationship between declining control rates, therapeutic benefits and sample size is fundamental and necessarily impacts the marginal efficiency of therapeutic innovation. Though adaptations may preserve control rates permitting innovations that are undoubtedly beneficial, better understanding this relationship may permit wiser allocation of research resources.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Fox, K. (2002) · European Heart Journal · doi:10.1053/euhj.2001.3081 · Cited by 599
Cited by
Empirical Evaluation of Very Large Treatment Effects of Medical Interventions
Pereira, T. V., Horwitz, R. I., & Ioannidis, J. P. A. (2012) · JAMA · doi:10.1001/jama.2012.13444 · Cited by 257
Critical Limb Ischemia: Current Trends and Future Directions
Teraa, M., Conte, M. S., Moll, F. L., & Verhaar, M. C. (2016) · Journal of the American Heart Association · doi:10.1161/jaha.115.002938 · Cited by 256
Dahabreh, I. J., Sheldrick, R. C., Paulus, J. K., Chung, M., Varvarigou, V., Jafri, H., Rassen, J. A., Trikalinos, T. A., & Kitsios, G. D. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs114 · Cited by 204
Composite End Points in Randomized Trials: There Is No Free Lunch
Tomlinson, G., & Detsky, A. S. (2010) · JAMA · doi:10.1001/jama.2009.2017 · Cited by 121
Risk factors and interventions with statistically significant tiny effects
Siontis, G. C., & Ioannidis, J. P. (2011) · International Journal of Epidemiology · doi:10.1093/ije/dyr099 · Cited by 80
Metadata
- Authors
- Kent, D. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2009-11-25
- Volume
- 302
- Issue
- 20
- Pages
- 2254
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1995356700
- Cited by
- 29
- References
- 1
- FWCI
- 9.62
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Therapeutic Innovations, Diminishing Returns, and Control Rate Preservation. https://app.cochat.ai/papers/10.1001/jama.2009.1679
- The paper
- Kent, D. M. (2009). Therapeutic Innovations, Diminishing Returns, and Control Rate Preservation. JAMA. https://doi.org/10.1001/jama.2009.1679
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.